Omnicell raises 2026 non-GAAP EPS outlook to $2.48–$2.56
Omnicell raised its full-year non-GAAP earnings outlook and reiterated its product bookings range.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Omnicell, Inc. (OMCL) reported third-quarter 2026 revenue of $307.851 million, down from $310.631 million a year earlier; the company described the decline as 1%. GAAP net income was $11.044 million, versus $5.462 million; non-GAAP net income was $27.039 million, versus $23.526 million. Non-GAAP EBITDA was $44.931 million, compared with $41.132 million, and operating cash flow was $33.052 million, versus $28.267 million. Revenue and profitability exceeded the high end of prior guidance.
Omnicell raised full-year 2026 non-GAAP EBITDA guidance to $187 million–$193 million and non-GAAP earnings per share to $2.48–$2.56. It tightened full-year total, product and service revenue guidance ranges and its annual recurring revenue range, and reiterated product bookings guidance of $425 million–$560 million. Full-year total revenue guidance is $1.225 billion–$1.231 billion and annual recurring revenue guidance is $660 million–$670 million. Fourth-quarter revenue guidance is $295 million–$301 million, with non-GAAP EBITDA guidance of $30 million–$36 million.
As of September 30, 2026, cash and cash equivalents were $314.856 million and debt, net of unamortized issuance costs, was $168.508 million. Omnicell had $350 million available under its revolving credit facility, with no outstanding balance.
5 points · 1 major0 major · 0 points
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 non-GAAP EBITDA guidance increased to $187 million–$193 million.
- Moderate pointThird-quarter GAAP net income was $11.044 million, versus $5.462 million.
- Moderate pointThird-quarter non-GAAP net income was $27.039 million, versus $23.526 million.
- Moderate pointThird-quarter non-GAAP EBITDA was $44.931 million, versus $41.132 million.
- Moderate pointThird-quarter operating cash flow was $33.052 million, versus $28.267 million.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Third-quarter total revenues: $307.851 million
Third-quarter GAAP net income: $11.044 million
Third-quarter non-GAAP net income: $27.039 million
+5 more
8 metrics
Third-quarter total revenues
$307.851 million
Three months ended September 30, 2026; $310.631 million in 2025
Third-quarter GAAP net income
$11.044 million
Three months ended September 30, 2026; $5.462 million in 2025
Third-quarter non-GAAP net income
$27.039 million
Three months ended September 30, 2026; $23.526 million in 2025
Third-quarter non-GAAP EBITDA
$44.931 million
Three months ended September 30, 2026; $41.132 million in 2025
Third-quarter net cash provided by operating activities
$33.052 million
Three months ended September 30, 2026; $28.267 million in 2025
Full-year total revenue guidance
$1.225 billion–$1.231 billion
2026 guidance
Full-year non-GAAP EBITDA guidance
$187 million–$193 million
2026 guidance; increased
Full-year non-GAAP earnings per share guidance
$2.48–$2.56
2026 guidance; increased
Key Terms
non-GAAP EBITDA, Annual Recurring Revenue, non-GAAP free cash flow, Convertible senior notes
4 terms
non-GAAP EBITDA financial
"Total non-GAAP EBITDA for the third quarter of 2026"
Non-GAAP EBITDA is a company's earnings before interest, taxes, depreciation and amortization that management adjusts by adding back or removing certain items that official accounting rules (GAAP) would normally include. Investors look at it to get a cleaner view of recurring operating performance—like checking a score after removing one-off events—but because companies decide which items to exclude, it can vary widely and should be evaluated alongside standard GAAP measures.
Annual Recurring Revenue financial
"Annual Recurring Revenue | Not provided"
Annual recurring revenue is the predictable amount of money a company expects to earn each year from ongoing customer subscriptions or contracts. It helps businesses understand how much steady income they can count on, much like a subscription service that charges customers every month or year. This figure is important because it shows the company's stability and growth potential.
non-GAAP free cash flow financial
"Reconciliation of GAAP net cash provided by operating activities to non-GAAP free cash flow"
Non-GAAP free cash flow is a company’s reported cash generated from operations after paying for routine investments in property and equipment, adjusted by management to exclude or include certain items that aren’t part of standard accounting rules. Investors watch it as a practical measure of the cash a business has available for dividends, stock buybacks, debt repayment or reinvestment — like a household’s usable savings after adjusting for one-time or unusual expenses — but calculations vary between firms, so comparisons require caution.
Convertible senior notes financial
"Convertible senior notes, net"
Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.
Earnings Snapshot
Total revenues: $307.851 million · Guidance included
Third quarter 2026
Total revenues
$307.851 million
Down $3 million, or 1%, from the third quarter of 2025
GAAP net income
$11.044 million
Compared with $5.462 million in the third quarter of 2025
Non-GAAP net income
$27.039 million
Compared with $23.526 million in the third quarter of 2025
Non-GAAP EBITDA
$44.931 million
Compared with $41.132 million in the third quarter of 2025
Net cash provided by operating activities
$33.052 million
Compared with $28.267 million in the third quarter of 2025
Guidance
For full-year 2026, non-GAAP EBITDA guidance increased to $187 million–$193 million and non-GAAP earnings per share guidance increased to $2.48–$2.56. Total revenue guidance is $1.225 billion–$1.231 billion, annual recurring revenue guidance is $660 million–$670 million, and product bookings guidance of $425 million–$560 million was reiterated.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is OMCL's 2026 financial guidance?
Omnicell's full-year 2026 guidance includes product bookings of $425 million–$560 million, annual recurring revenue of $660 million–$670 million, total revenue of $1.225 billion–$1.231 billion, product revenue of $684 million–$687 million, and service revenue of $541 million–$544 million. Non-GAAP EBITDA guidance is $187 million–$193 million and non-GAAP earnings per share guidance is $2.48–$2.56. The company raised EBITDA and earnings-per-share guidance, tightened revenue and annual recurring revenue ranges, and reiterated product bookings guidance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 29, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||||||||
(Address of principal executive offices, including zip code)
(877 ) 415-9990
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||||||||
| Emerging growth company | |||||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | |||||||||||
Item 2.02 Results of Operations and Financial Condition.
On October 29, 2026, Omnicell, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and updating its guidance for the full year 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Exhibit Description | |||||||
| 99.1 | Press release entitled “Omnicell Announces Third Quarter 2026 Financial Results” dated October 29, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| OMNICELL, INC. | |||||||||||
Date: October 29, 2026 | /s/ H. Baird Radford, III | ||||||||||
| Baird Radford | |||||||||||
| Executive Vice President and Chief Financial Officer | |||||||||||
Exhibit 99.1
| Contact: | Omnicell, Inc. | |||||||
| David Unger | 4220 North Freeway | |||||||
| Vice President, Investor Relations | Fort Worth, TX 76137 | |||||||
| ir@omnicell.com | ||||||||
Omnicell Announces Third Quarter 2026 Financial Results
Omnicell delivers solid third quarter 2026 financial results
Updates full year 2026 guidance
FORT WORTH, Texas -- October 29, 2026 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” or the “Company”), a healthcare technology leader focused on advancing autonomous medication management, today reported financial results for the third quarter ended September 30, 2026.
Third quarter results reflected continued execution across the business, supported by demand for Omnicell’s connected device portfolio, favorable product and service margins and disciplined cost management. Our business performed well during the quarter, with revenue and profitability both coming in above the high end of our previously provided guidance range, and we continue to see healthcare providers prioritize solutions that are designed to improve operational efficiency, optimize medication workflows, and help address ongoing workforce challenges.
“We delivered solid third quarter results and continued to execute against our strategic priorities,” said Randall A. Lipps, chairman, chief executive officer, and founder of Omnicell. “We believe our performance reflects the discipline we have built into the business throughout the year, combined with continued customer interest in solutions that are designed to improve efficiency, safety, and workforce productivity across medication management.”
“At the same time, we continue to see strong momentum with our next-generation platform, backed by a growing pipeline,” Lipps added. “Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform, intended to improve productivity, efficiency, and workflow reliability. As we see health systems seek greater visibility and connectivity across the medication-use process, we believe Omnicell Titan XT and OmniSphere position us to capitalize on a significant long-term opportunity we see in autonomous medication management.”
Financial Results
Total revenues for the third quarter of 2026 were $308 million, down $3 million, or 1%, from the third quarter of 2025.
Total GAAP net income for the third quarter of 2026 was $11 million, or $0.24 per diluted share. This compares to GAAP net income of $5 million, or $0.12 per diluted share, for the third quarter of 2025.
Total non-GAAP net income for the third quarter of 2026 was $27 million, or $0.58 per diluted share. This compares to non-GAAP net income of $24 million, or $0.51 per diluted share, for the third quarter of 2025.
Total non-GAAP EBITDA for the third quarter of 2026 was $45 million. This compares to non-GAAP EBITDA of $41 million for the third quarter of 2025.
Balance Sheet
As of September 30, 2026, Omnicell’s balance sheet reflected cash and cash equivalents of $315 million, total debt (net of unamortized debt issuance costs) of $169 million, and total assets of $2.1 billion. Cash flows provided by operating activities in the
1
third quarter of 2026 totaled $33 million. This compares to cash flows provided by operating activities totaling $28 million in the third quarter of 2025.
As of September 30, 2026, the Company had $350 million of availability under its revolving credit facility with no outstanding balance.
Corporate Highlights
•Over 200 healthcare leaders and industry experts joined Omnicell for the sixth annual Illuminate, a virtual education and best practice sharing event. Panel discussions focused on real-world experiences building connected, intelligent medication management strategies that are designed to help drive meaningful clinical, operational, and financial outcomes.
•Issued the 2025 Environmental, Social, and Governance (ESG) Report, which reflects Omnicell’s ongoing commitment to ESG principles. Guided by innovation, the Report highlights the Company’s continuous focus on advancing autonomous medication management while supporting a more sustainable and patient-centered healthcare ecosystem.
2026 Guidance
The table below summarizes Omnicell’s fourth quarter and updated full year 2026 guidance. Given our strong third quarter 2026 profitability performance and continued focus on disciplined execution, we are increasing our full year 2026 non-GAAP EBITDA and non-GAAP earnings per share guidance ranges. In addition, as we are through the first three quarters of the year, we are tightening our full year 2026 total, product, and service revenues guidance ranges. We are also tightening our full year 2026 annual recurring revenue guidance range, with the low end unchanged, reflecting our increased visibility into the business as we approach year end. We are reiterating our product bookings guidance range, which continues to reflect our current assessment of the range of potential outcomes for full year 2026.
| Q4 2026 | 2026 | ||||||||||
| Product Bookings | Not provided | $425 million - $560 million | |||||||||
| Annual Recurring Revenue | Not provided | $660 million - $670 million | |||||||||
| Total Revenues | $295 million - $301 million | $1.225 billion - $1.231 billion | |||||||||
| Product Revenues | $161 million - $164 million | $684 million - $687 million | |||||||||
| Service Revenues | $134 million - $137 million | $541 million - $544 million | |||||||||
| Technical Services Revenues | Not provided | $272 million - $273 million | |||||||||
| SaaS and Expert Service Revenues | Not provided | $269 million - $271 million | |||||||||
| Non-GAAP EBITDA | $30 million - $36 million | $187 million - $193 million | |||||||||
| Non-GAAP Earnings Per Share | $0.41 - $0.49 | $2.48 - $2.56 | |||||||||
The Company does not provide guidance for GAAP net income or GAAP earnings per share, nor a reconciliation of any forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because it is unable to predict certain items contained in the GAAP measures without unreasonable efforts. These forward-looking non-GAAP financial measures do not include certain items, which may be significant, including, but not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes.
Omnicell Conference Call Information
Omnicell will hold a conference call today, Thursday, October 29, 2026, at 8:30 a.m. ET to discuss third quarter 2026 financial results. The conference call can be monitored by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 574173299. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/events-and-presentations/.
2
About Omnicell
Omnicell is a healthcare technology leader focused on advancing autonomous medication management to drive meaningful outcomes across the patient care journey. Through AI-enabled innovation, enterprise intelligence, and scalable automation, we seek to connect and optimize medication management from orders to outcomes, empowering healthcare organizations worldwide to improve efficiency, enhance safety, strengthen financial performance, and deliver better experiences for patients and care teams. Learn more at omnicell.com.
From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).
OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries. This press release may also include the trademarks and service marks of other companies. Such trademarks and service marks are the marks of their respective owners.
Forward-Looking Statements
To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control.
Such statements include, but are not limited to, Omnicell’s projected product bookings, revenues, including product, service, technical services and SaaS and Expert Services revenues, annual recurring revenue, non-GAAP EBITDA, and non-GAAP earnings per share; expectations regarding demand for, and customer interest in, our products and services, developing new or enhancing existing products and solutions and the related objectives and expected benefits (and any implied financial impact); Omnicell’s ability to maintain focus on operational discipline and execute against its strategic priorities; the ability for our next-generation platform to support our customers’ needs; the long-term opportunity the next-generation platform represents, and statements about Omnicell’s strategy, plans, objectives, promise and purpose, vision, goals, opportunities, and market or Company outlook.
Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including longer timeframes for purchasing decisions and entering into agreements for our products or solutions, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) Omnicell’s ability to successfully achieve anticipated growth targets or market adoption, (v) delays in installations of our medication management solutions or our more complex medication packaging systems, including the variability and difficulty in predicting purchasing decisions, for both current customers and competitive conversion opportunities being, difficulty forecasting product bookings due to the size and mix of potential customer opportunities or that the announcement of Titan XT may influence or impact purchasing decisions, including the timing of those decisions, (vi) delays, technical challenges and unexpected or greater than anticipated expenses associated with developing new products and services or failing to achieve technological or economic feasibility, obtain regulatory approval or gain market acceptance, (vii) the potential impact of periods of significant volatility due to geopolitical developments, (viii) the risk of increased credit, collection, and operational challenges from providing lease financing options to our customers, (ix) risks related to the incorporation of artificial intelligence technologies, including generative or agentic AI technologies, into our products, services and processes or our vendors offerings, (x) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xi) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (xii) Omnicell’s ability to meet the demands of, or maintain relationships with, GPOs and its institutional, retail, and specialty pharmacy customers, (xiii) the inability to secure or maintain access to existing and future specialty drugs or pharmacy provider networks for our specialty pharmacy customers, (xiv) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (xv) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses or technologies and successfully integrate such acquisitions, (xvi) Omnicell’s substantial debt, (xvii) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental
3
investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same, (xviii) changes to the 340B Program, (xix) our international operations may subject us to additional risks, including from the impact of tariffs, (xx) covenants in our credit agreement could restrict our business and operations, (xxi) exposure to liquidity and counterparty risk as a result of financial institution and money market fund concentration, (xxii) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (xxiii) catastrophic events, (xxiv) Omnicell’s ability to recruit and retain skilled and motivated personnel, (xxv) Omnicell’s ability to protect its intellectual property, (xxvi) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xxvii) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, (xxviii) fluctuations in quarterly and annual operating results may make our future operating results difficult to predict, (xxix) failing to meet (or significantly exceeding) our publicly announced financial guidance, and (xxx) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Readers are encouraged to review this press release in conjunction with our most recent Annual Report on Form 10-K and our other reports filed with or furnished to the SEC. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.
Use of Non-GAAP Financial Information
This press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Management evaluates and makes operating decisions using various performance measures. In addition to Omnicell’s GAAP results, we also consider non-GAAP product gross profit, non-GAAP product gross margin, non-GAAP service gross profit, non-GAAP service gross margin, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP diluted shares, non-GAAP EBITDA, non-GAAP EBITDA margin, and non-GAAP free cash flow. These non-GAAP results and metrics should not be considered as an alternative to revenues, product gross profit, service gross profit, gross profit, operating expenses, income from operations, net income, net income per diluted share, diluted shares, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results and metrics because management considers them to be important supplemental measures of Omnicell’s performance and refers to such measures when analyzing Omnicell’s strategy and operations.
Our non-GAAP product gross profit, non-GAAP product gross margin, non-GAAP service gross profit, non-GAAP service gross margin, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin are exclusive of certain items to facilitate management’s review of the comparability of Omnicell’s core operating results on a period-to-period basis because such items are not related to Omnicell’s ongoing core operating results as viewed by management. We define our “core operating results” as those revenues recorded in a particular period and the expenses incurred within such period that directly drive operating income in such period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we believe we should invest in research and development, fund infrastructure growth, and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results: non-GAAP product gross profit and non-GAAP product gross margin exclude from their GAAP equivalents items a), b), and h) below; non-GAAP service gross profit and non-GAAP service gross margin exclude from their GAAP equivalents a), b), and j) below; non-GAAP gross profit and non-GAAP gross margin exclude from their GAAP equivalents items a), b), h) and j) below; non-GAAP operating expenses, non-GAAP income from operations and non-GAAP operating margin exclude from their GAAP equivalents items a), b), c), e), f), g), h), i), j) and k) below; and non-GAAP net income and non-GAAP net income per diluted share exclude from their GAAP equivalents items a) through k) below. Non-GAAP EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Non-GAAP EBITDA and non-GAAP EBITDA margin exclude from their GAAP equivalents items a), c), d), e), f), g), h), i), j) and k) below:
a)Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Omnicell.
b)Amortization of acquired intangible assets. We excluded from our non-GAAP results the intangible assets amortization expense resulting from our past acquisitions. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.
4
c)Acquisition-related expenses. We excluded from our non-GAAP results the expenses related to recent acquisitions, including amortization of representations and warranties insurance. These expenses are unrelated to our ongoing operations, vary in size and frequency, and are subject to significant fluctuations from period to period due to varying levels of acquisition activity. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
d)Amortization of debt issuance costs. Debt issuance costs represent costs associated with the issuance of revolving credit facilities and convertible senior notes. The costs include underwriting fees, original issue discount, ticking fees, and legal fees. These non-cash expenses are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.
e)Legal and regulatory expenses. We excluded from our non-GAAP results certain non-recurring legal and regulatory expenses, representing settlement amounts, related to certain claims of non-compliance with our government contracts that are outside of the ordinary course of our business. We believe that excluding these amounts provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
f)Management severance costs. We excluded from our non-GAAP results the severance expense of certain senior management associated with the restructuring of our senior leadership team. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
g)Executives transition costs. We excluded from our non-GAAP results the transition costs associated with the departure of a certain executive officer, primarily consisting of severance expenses. These expenses are unrelated to our ongoing operations and we do not expect them to occur in the ordinary course of business. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
h)Professional Services restructuring costs. We excluded from our non-GAAP results nonrecurring restructuring charges related to organizational and resource adjustments within Professional Services to improve scalability and better align with evolving customer needs. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
i)Product organization restructuring costs. We excluded from our non-GAAP results the nonrecurring charges related to the restructuring of the product organization to better align teams, resources, and priorities with our strategic goals and future growth plans. These charges consisted primarily of severance and other related expenses. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
j)EnlivenHealth restructuring costs. We excluded from our non-GAAP results the nonrecurring charges primarily related to restructuring within the EnlivenHealth business as we seek to gain operational efficiency and synergy, and adapt to the recent industry dynamics within the retail pharmacy space. These charges consisted primarily of severance and other related expenses. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
k)China restructuring costs. We excluded from our non-GAAP results the nonrecurring restructuring charges related to the exit of our Beijing, China office as part of our operating model adjustments. These charges consisted primarily of severance and other related expenses. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.
Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell’s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.
We believe that the presentation of non-GAAP product gross profit, non-GAAP product gross margin, non-GAAP service gross profit, non-GAAP service gross margin, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-
5
GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin is warranted for several reasons:
a)Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell’s financial performance by excluding the impact of items which may obscure trends in the core operating results of the business.
b)Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors’ ability to compare our performance across financial reporting periods.
c)These non-GAAP financial measures are employed by management in its own evaluation of performance and are utilized in financial and operational decision-making processes, such as budget planning and forecasting.
d)These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which also use non-GAAP financial measures to supplement their GAAP results (although these companies may calculate non-GAAP financial measures differently than Omnicell does), thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.
Set forth below are additional reasons why share-based compensation expense is excluded from our non-GAAP financial measures:
i)While share-based compensation calculated in accordance with Accounting Standards Codification (“ASC”) 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of share-based compensation expense to assist management and investors in evaluating our core operating results.
ii)We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation under ASC 718 are dependent upon the trading price of Omnicell’s common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties, the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.
Non-GAAP diluted shares is defined as our GAAP diluted shares, excluding the impact of dilutive convertible senior notes for which the Company is economically hedged through its anti-dilutive convertible note hedge transaction. Additionally, in a period of net loss, GAAP diluted shares are further adjusted for certain shares whose effect would be dilutive in a period of net income. We believe non-GAAP diluted shares is a useful non-GAAP metric because it provides insight into the offsetting economic effect of the hedge transaction against potential conversion of the convertible senior notes.
Non-GAAP free cash flow is defined as net cash provided by operating activities less cash used for software development for external use and purchases of property and equipment. We believe free cash flow is important to enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review and understanding of our overall financial, operational, and economic performance, because free cash flow takes into account certain capital expenditures and cash used for software development necessary to operate our business.
As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell’s GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:
a)Omnicell’s equity incentive plans and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell’s GAAP results for the foreseeable future under ASC 718.
b)Other companies, including companies in Omnicell’s industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure.
c)A limitation of the utility of free cash flow as a measure of financial performance is that it does not represent the total increase or decrease in Omnicell’s cash balance for the period.
A detailed reconciliation between Omnicell’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Omnicell’s other reports filed with or furnished to the SEC.
6
Omnicell, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Product revenues | $ | 173,052 | $ | 177,498 | $ | 522,914 | $ | 485,838 | |||||||||||||||
Service revenues | 134,799 | 133,133 | 407,025 | 385,023 | |||||||||||||||||||
| Total revenues | 307,851 | 310,631 | 929,939 | 870,861 | |||||||||||||||||||
Cost of revenues: | |||||||||||||||||||||||
| Cost of product revenues | 98,222 | 96,741 | 279,408 | 274,245 | |||||||||||||||||||
Cost of service revenues | 71,803 | 79,387 | 219,407 | 223,499 | |||||||||||||||||||
| Total cost of revenues | 170,025 | 176,128 | 498,815 | 497,744 | |||||||||||||||||||
Gross profit | 137,826 | 134,503 | 431,124 | 373,117 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
| Research and development | 22,352 | 24,021 | 64,170 | 66,120 | |||||||||||||||||||
| Selling, general, and administrative | 100,541 | 102,238 | 302,718 | 302,252 | |||||||||||||||||||
| Total operating expenses | 122,893 | 126,259 | 366,888 | 368,372 | |||||||||||||||||||
| Income from operations | 14,933 | 8,244 | 64,236 | 4,745 | |||||||||||||||||||
| Interest and other income (expense), net | 871 | 1,459 | 2,306 | 5,881 | |||||||||||||||||||
| Income before income taxes | 15,804 | 9,703 | 66,542 | 10,626 | |||||||||||||||||||
| Provision for income taxes | 4,760 | 4,241 | 19,851 | 6,548 | |||||||||||||||||||
| Net income | $ | 11,044 | $ | 5,462 | $ | 46,691 | $ | 4,078 | |||||||||||||||
| Net income per share: | |||||||||||||||||||||||
| Basic | $ | 0.24 | $ | 0.12 | $ | 1.02 | $ | 0.09 | |||||||||||||||
| Diluted | $ | 0.24 | $ | 0.12 | $ | 1.01 | $ | 0.09 | |||||||||||||||
| Weighted-average shares outstanding: | |||||||||||||||||||||||
| Basic | 45,893 | 45,540 | 45,610 | 46,304 | |||||||||||||||||||
| Diluted | 46,466 | 45,900 | 46,269 | 46,657 | |||||||||||||||||||
7
Omnicell, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)
| September 30, 2026 | December 31, 2025 | ||||||||||
ASSETS | |||||||||||
Current assets: | |||||||||||
| Cash and cash equivalents | $ | 314,856 | $ | 196,520 | |||||||
| Accounts receivable and unbilled receivables, net | 236,046 | 216,858 | |||||||||
| Inventories | 98,278 | 100,905 | |||||||||
| Prepaid expenses | 50,631 | 33,709 | |||||||||
| Other current assets | 84,170 | 132,077 | |||||||||
| Total current assets | 783,981 | 680,069 | |||||||||
Property and equipment, net | 124,302 | 120,111 | |||||||||
Long-term investment in sales-type leases, net | 67,302 | 60,742 | |||||||||
Operating lease right-of-use assets | 23,097 | 24,366 | |||||||||
Goodwill | 737,125 | 737,946 | |||||||||
Intangible assets, net | 156,373 | 170,105 | |||||||||
Long-term deferred tax assets | 44,886 | 58,337 | |||||||||
Prepaid commissions | 52,623 | 52,840 | |||||||||
Other long-term assets | 67,147 | 70,204 | |||||||||
| Total assets | $ | 2,056,836 | $ | 1,974,720 | |||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities: | |||||||||||
| Accounts payable | $ | 60,824 | $ | 43,990 | |||||||
| Accrued compensation | 68,335 | 57,172 | |||||||||
| Accrued liabilities | 144,749 | 203,586 | |||||||||
Deferred revenues | 199,789 | 171,861 | |||||||||
| Total current liabilities | 473,697 | 476,609 | |||||||||
Long-term deferred revenues | 63,792 | 63,254 | |||||||||
| Long-term deferred tax liabilities | 640 | 683 | |||||||||
Long-term operating lease liabilities | 21,161 | 24,794 | |||||||||
Other long-term liabilities | 11,783 | 9,970 | |||||||||
| Convertible senior notes, net | 168,508 | 167,596 | |||||||||
| Total liabilities | 739,581 | 742,906 | |||||||||
| Total stockholders’ equity | 1,317,255 | 1,231,814 | |||||||||
| Total liabilities and stockholders’ equity | $ | 2,056,836 | $ | 1,974,720 | |||||||
8
Omnicell, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)
| Nine Months Ended September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Operating Activities | |||||||||||
| Net income | $ | 46,691 | $ | 4,078 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 55,812 | 58,984 | |||||||||
| Loss on disposal of assets | 440 | 408 | |||||||||
| Share-based compensation expense | 33,122 | 32,526 | |||||||||
| Deferred income taxes | 13,408 | 1,233 | |||||||||
| Amortization of operating lease right-of-use assets | 5,762 | 5,868 | |||||||||
| Impairment of external-use software development costs | 122 | — | |||||||||
| Amortization of debt issuance costs | 1,494 | 2,155 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable and unbilled receivables | (19,188) | 12,450 | |||||||||
| Inventories | 2,627 | (17,731) | |||||||||
| Prepaid expenses | (16,922) | (4,305) | |||||||||
| Other current assets | (12,611) | (10,037) | |||||||||
| Investment in sales-type leases | (8,212) | (2,493) | |||||||||
| Prepaid commissions | 217 | 2,097 | |||||||||
| Other long-term assets | (2,673) | 5,919 | |||||||||
| Accounts payable | 18,245 | 10,695 | |||||||||
| Accrued compensation | 11,163 | (10,999) | |||||||||
| Accrued liabilities | 4,805 | (13,059) | |||||||||
| Deferred revenues | 28,737 | 26,901 | |||||||||
| Operating lease liabilities | (8,986) | (8,753) | |||||||||
| Other long-term liabilities | 1,813 | 1,009 | |||||||||
| Net cash provided by operating activities | 155,866 | 96,946 | |||||||||
| Investing Activities | |||||||||||
| External-use software development costs | (8,765) | (13,237) | |||||||||
| Purchases of property and equipment | (32,738) | (32,706) | |||||||||
| Net cash used in investing activities | (41,503) | (45,943) | |||||||||
| Financing Activities | |||||||||||
| Repayment of convertible senior notes due 2025 | — | (175,000) | |||||||||
| Proceeds from issuances under stock-based compensation plans | 14,014 | 15,162 | |||||||||
| Employees’ taxes paid related to restricted stock units | (7,826) | (5,963) | |||||||||
| Excise tax paid on common stock repurchases | (388) | — | |||||||||
Common stock repurchases | — | (77,600) | |||||||||
| Change in customer funds, net | (31,713) | 15,989 | |||||||||
| Net cash used in financing activities | (25,913) | (227,412) | |||||||||
| Effect of exchange rate changes on cash and cash equivalents | (1,827) | 3,250 | |||||||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 86,623 | (173,159) | |||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 251,032 | 398,614 | |||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 337,655 | $ | 225,455 | |||||||
| Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets: | |||||||||||
| Cash and cash equivalents | $ | 314,856 | $ | 180,053 | |||||||
| Restricted cash included in other current assets | 22,799 | 45,402 | |||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 337,655 | $ | 225,455 | |||||||
9
Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands, except per share data and percentage)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Reconciliation of GAAP product gross profit to non-GAAP product gross profit: | |||||||||||||||||||||||
| GAAP product revenues | $ | 173,052 | $ | 177,498 | $ | 522,914 | $ | 485,838 | |||||||||||||||
| GAAP cost of product revenues | 98,222 | 96,741 | 279,408 | 274,245 | |||||||||||||||||||
| GAAP product gross profit | $ | 74,830 | $ | 80,757 | $ | 243,506 | $ | 211,593 | |||||||||||||||
| GAAP product gross margin | 43.2% | 45.5% | 46.6% | 43.6% | |||||||||||||||||||
| Share-based compensation expense | 601 | 277 | 1,850 | 1,721 | |||||||||||||||||||
| Amortization of acquired intangibles | 333 | 332 | 998 | 1,014 | |||||||||||||||||||
| Professional Services restructuring | — | — | 1,630 | — | |||||||||||||||||||
| Non-GAAP product gross profit | $ | 75,764 | $ | 81,366 | $ | 247,984 | $ | 214,328 | |||||||||||||||
| Non-GAAP product gross margin | 43.8% | 45.8% | 47.4% | 44.1% | |||||||||||||||||||
| Reconciliation of GAAP service gross profit to non-GAAP service gross profit: | |||||||||||||||||||||||
| GAAP service revenues | $ | 134,799 | $ | 133,133 | $ | 407,025 | $ | 385,023 | |||||||||||||||
| GAAP cost of service revenues | 71,803 | 79,387 | 219,407 | 223,499 | |||||||||||||||||||
| GAAP service gross profit | $ | 62,996 | $ | 53,746 | $ | 187,618 | $ | 161,524 | |||||||||||||||
| GAAP service gross margin | 46.7% | 40.4% | 46.1% | 42.0% | |||||||||||||||||||
| Share-based compensation expense | 817 | 719 | 2,472 | 2,200 | |||||||||||||||||||
| Amortization of acquired intangibles | 289 | 654 | 908 | 1,966 | |||||||||||||||||||
| EnlivenHealth restructuring | — | 892 | — | 892 | |||||||||||||||||||
| Non-GAAP service gross profit | $ | 64,102 | $ | 56,011 | $ | 190,998 | $ | 166,582 | |||||||||||||||
| Non-GAAP service gross margin | 47.6% | 42.1% | 46.9% | 43.3% | |||||||||||||||||||
| Reconciliation of GAAP gross profit to non-GAAP gross profit: | |||||||||||||||||||||||
| GAAP gross profit | $ | 137,826 | $ | 134,503 | $ | 431,124 | $ | 373,117 | |||||||||||||||
| GAAP gross margin | 44.8% | 43.3% | 46.4% | 42.8% | |||||||||||||||||||
| Share-based compensation expense | 1,418 | 996 | 4,322 | 3,921 | |||||||||||||||||||
| Amortization of acquired intangibles | 622 | 986 | 1,906 | 2,980 | |||||||||||||||||||
| Professional Services restructuring | — | — | 1,630 | — | |||||||||||||||||||
| EnlivenHealth restructuring | — | 892 | — | 892 | |||||||||||||||||||
| Non-GAAP gross profit | $ | 139,866 | $ | 137,377 | $ | 438,982 | $ | 380,910 | |||||||||||||||
| Non-GAAP gross margin | 45.4% | 44.2% | 47.2% | 43.7% | |||||||||||||||||||
| Reconciliation of GAAP operating expenses to non-GAAP operating expenses: | |||||||||||||||||||||||
| GAAP operating expenses | $ | 122,893 | $ | 126,259 | $ | 366,888 | $ | 368,372 | |||||||||||||||
| GAAP operating expenses % to total revenues | 39.9% | 40.6% | 39.5% | 42.3% | |||||||||||||||||||
| Share-based compensation expense | (9,999) | (10,214) | (28,800) | (28,605) | |||||||||||||||||||
| Amortization of acquired intangibles | (3,840) | (4,248) | (11,715) | (13,283) | |||||||||||||||||||
| Acquisition-related expenses | (182) | (182) | (546) | (546) | |||||||||||||||||||
| China restructuring | (652) | — | (652) | — | |||||||||||||||||||
| Professional Services restructuring | — | — | (131) | — | |||||||||||||||||||
| Product organization restructuring | — | — | (1,929) | — | |||||||||||||||||||
| EnlivenHealth restructuring | — | (1,674) | — | (1,674) | |||||||||||||||||||
| Legal and regulatory expenses | — | — | — | (2,700) | |||||||||||||||||||
| Management severance costs | — | — | — | (562) | |||||||||||||||||||
| Executives transition costs | — | — | — | (968) | |||||||||||||||||||
| Non-GAAP operating expenses | $ | 108,220 | $ | 109,941 | $ | 323,115 | $ | 320,034 | |||||||||||||||
| Non-GAAP operating expenses as a % of total revenues | 35.2% | 35.4% | 34.7% | 36.7% | |||||||||||||||||||
10
Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands, except per share data and percentage)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Reconciliation of GAAP income from operations to non-GAAP income from operations: | |||||||||||||||||||||||
| GAAP income from operations | $ | 14,933 | $ | 8,244 | $ | 64,236 | $ | 4,745 | |||||||||||||||
| GAAP operating income % to total revenues | 4.9% | 2.7% | 6.9% | 0.5% | |||||||||||||||||||
| Share-based compensation expense | 11,417 | 11,210 | 33,122 | 32,526 | |||||||||||||||||||
| Amortization of acquired intangibles | 4,462 | 5,234 | 13,621 | 16,263 | |||||||||||||||||||
| Acquisition-related expenses | 182 | 182 | 546 | 546 | |||||||||||||||||||
| China restructuring | 652 | — | 652 | — | |||||||||||||||||||
| Professional Services restructuring | — | — | 1,761 | — | |||||||||||||||||||
| Product organization restructuring | — | — | 1,929 | — | |||||||||||||||||||
| EnlivenHealth restructuring | — | 2,566 | — | 2,566 | |||||||||||||||||||
| Legal and regulatory expenses | — | — | — | 2,700 | |||||||||||||||||||
| Management severance costs | — | — | — | 562 | |||||||||||||||||||
| Executives transition costs | — | — | — | 968 | |||||||||||||||||||
| Non-GAAP income from operations | $ | 31,646 | $ | 27,436 | $ | 115,867 | $ | 60,876 | |||||||||||||||
| Non-GAAP operating margin (non-GAAP operating income as a % of total revenues) | 10.3% | 8.8% | 12.5% | 7.0% | |||||||||||||||||||
Reconciliation of GAAP net income to non-GAAP net income: | |||||||||||||||||||||||
| GAAP net income | $ | 11,044 | $ | 5,462 | $ | 46,691 | $ | 4,078 | |||||||||||||||
| Share-based compensation expense | 11,417 | 11,210 | 33,122 | 32,526 | |||||||||||||||||||
| Amortization of acquired intangibles | 4,462 | 5,234 | 13,621 | 16,263 | |||||||||||||||||||
Acquisition-related expenses | 182 | 182 | 546 | 546 | |||||||||||||||||||
| China restructuring | 652 | — | 652 | — | |||||||||||||||||||
| Professional Services restructuring | — | — | 1,761 | — | |||||||||||||||||||
| Product organization restructuring | — | — | 1,929 | — | |||||||||||||||||||
| EnlivenHealth restructuring | — | 2,566 | — | 2,566 | |||||||||||||||||||
| Legal and regulatory expenses | — | — | — | 2,700 | |||||||||||||||||||
| Management severance costs | — | — | — | 562 | |||||||||||||||||||
| Executives transition costs | — | — | — | 968 | |||||||||||||||||||
| Amortization of debt issuance costs | 499 | 694 | 1,494 | 2,155 | |||||||||||||||||||
Tax effect of the adjustments above (a) | (1,217) | (1,822) | (4,201) | (5,410) | |||||||||||||||||||
| Non-GAAP net income | $ | 27,039 | $ | 23,526 | $ | 95,615 | $ | 56,954 | |||||||||||||||
______________________________________________
(a)Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2026 and 2025.
11
Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands, except per share data and percentage)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Reconciliation of GAAP net income per share - diluted to non-GAAP net income per share - diluted: | |||||||||||||||||||||||
| Shares - diluted GAAP | 46,466 | 45,900 | 46,269 | 46,657 | |||||||||||||||||||
| Shares - diluted non-GAAP | 46,466 | 45,900 | 46,269 | 46,657 | |||||||||||||||||||
| GAAP net income per share - diluted | $ | 0.24 | $ | 0.12 | $ | 1.01 | $ | 0.09 | |||||||||||||||
| Share-based compensation expense | 0.25 | 0.24 | 0.73 | 0.70 | |||||||||||||||||||
| Amortization of acquired intangibles | 0.10 | 0.11 | 0.29 | 0.35 | |||||||||||||||||||
| Acquisition-related expenses | 0.00 | 0.00 | 0.01 | 0.01 | |||||||||||||||||||
| China restructuring | 0.01 | — | 0.01 | — | |||||||||||||||||||
| Professional Services restructuring | — | — | 0.04 | — | |||||||||||||||||||
| Product organization restructuring | — | — | 0.04 | — | |||||||||||||||||||
| EnlivenHealth restructuring | — | 0.06 | — | 0.05 | |||||||||||||||||||
| Legal and regulatory expenses | — | — | — | 0.06 | |||||||||||||||||||
| Management severance costs | — | — | — | 0.01 | |||||||||||||||||||
| Executives transition costs | — | — | — | 0.02 | |||||||||||||||||||
| Amortization of debt issuance costs | 0.01 | 0.02 | 0.03 | 0.05 | |||||||||||||||||||
Tax effect of the adjustments above (a) | (0.03) | (0.04) | (0.09) | (0.12) | |||||||||||||||||||
| Non-GAAP net income per share - diluted | $ | 0.58 | $ | 0.51 | $ | 2.07 | $ | 1.22 | |||||||||||||||
Reconciliation of GAAP net income to non-GAAP EBITDA (b): | |||||||||||||||||||||||
| GAAP net income | $ | 11,044 | $ | 5,462 | $ | 46,691 | $ | 4,078 | |||||||||||||||
| Share-based compensation expense | 11,417 | 11,210 | 33,122 | 32,526 | |||||||||||||||||||
| Interest (income) and expense, net | (2,031) | (2,625) | (5,045) | (8,533) | |||||||||||||||||||
| Depreciation and amortization expense | 18,408 | 19,402 | 55,812 | 58,984 | |||||||||||||||||||
| Acquisition-related expenses | 182 | 182 | 546 | 546 | |||||||||||||||||||
| China restructuring | 652 | — | 652 | — | |||||||||||||||||||
| Professional Services restructuring | — | — | 1,761 | — | |||||||||||||||||||
| Product organization restructuring | — | — | 1,929 | — | |||||||||||||||||||
| EnlivenHealth restructuring | — | 2,566 | — | 2,566 | |||||||||||||||||||
| Legal and regulatory expenses | — | — | — | 2,700 | |||||||||||||||||||
| Management severance costs | — | — | — | 562 | |||||||||||||||||||
| Executives transition costs | — | — | — | 968 | |||||||||||||||||||
| Amortization of debt issuance costs | 499 | 694 | 1,494 | 2,155 | |||||||||||||||||||
| Provision for income taxes | 4,760 | 4,241 | 19,851 | 6,548 | |||||||||||||||||||
| Non-GAAP EBITDA | $ | 44,931 | $ | 41,132 | $ | 156,813 | $ | 103,100 | |||||||||||||||
| Non-GAAP EBITDA margin (non-GAAP EBITDA as a % of total revenues) | 14.6% | 13.2% | 16.9% | 11.8% | |||||||||||||||||||
(a)Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2026 and 2025.
(b)Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments.
12
Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Reconciliation of GAAP net cash provided by operating activities to non-GAAP free cash flow: | |||||||||||||||||||||||
| GAAP net cash provided by operating activities | $ | 33,052 | $ | 28,267 | $ | 155,866 | $ | 96,946 | |||||||||||||||
| External-use software development costs | (1,742) | (4,528) | (8,765) | (13,237) | |||||||||||||||||||
| Purchases of property and equipment | (11,363) | (9,753) | (32,738) | (32,706) | |||||||||||||||||||
| Non-GAAP free cash flow | $ | 19,947 | $ | 13,986 | $ | 114,363 | $ | 51,003 | |||||||||||||||
13